Review Article Open Access
Volume 3 | Issue 2 | DOI: https://doi.org/10.33696/cancerimmunol.3.047

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma

  • 1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
  • 2Section of Urologic Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA
  • 3Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA
  • #Equal author contribution
+ Affiliations - Affiliations

*Corresponding Author

Eric A. Singer, eric.singer@rutgers.edu

Received Date: November 23, 2020

Accepted Date: March 24, 2021


Urothelial carcinoma is one of the most common cancers in the United States, yet outcomes are historically suboptimal. Since 2016, the approval of five programmed cell death 1 and programmed death-ligand 1 immune checkpoint inhibitors for locally advanced and metastatic urothelial carcinoma has led to improved oncologic outcomes for many patients in the second-line setting. Two checkpoint inhibitors, pembrolizumab and atezolizumab subsequently earned approval for first-line therapy with restricted indications. More recently, pembrolizumab was approved for bacillus Calmette-Guérin-unresponsive high-risk non-muscle invasive bladder cancer, opening the door for other immune checkpoint inhibitors to be integrated into treatment in earlier disease stages. Recent bacillus Calmette-Guérin shortages have highlighted the need for alternative treatment options for patients with non-muscle invasive bladder cancer. Currently, there are no FDA-approved checkpoint inhibitors for non-metastatic muscle-invasive bladder cancer. Furthermore, many patients are ineligible for standard cisplatin-based chemotherapy regimens. Numerous ongoing clinical trials are employing immune checkpoint inhibitors for muscle-invasive bladder cancer patients in the neoadjuvant, adjuvant, perioperative, and bladdersparing setting. Although up to 10% of urothelial carcinoma tumors arise in the upper urinary tract, few studies are designed for this population. We highlight the need for more trials designed for patients with upper tract disease. Overall, there are numerous clinical trials investigating the safety and efficacy of immune checkpoint inhibitors in all stages of disease as single-agents and combined with dual-immune checkpoint inhibition, chemotherapy, radiotherapy, and other pharmacologic agents. As the field continues to evolve rapidly, we aim to provide an overview of recent and ongoing immunotherapy clinical trials in urothelial carcinoma.


Urothelial carcinoma (UC), Bladder cancer, Upper tract urothelial carcinoma (UTUC), Immunotherapy, Immune checkpoint inhibitors, PD-1, PD-L1


Bladder cancer is one of the most common and expensive cancers in the United States, with an expected 81,400 new cases and 17,980 deaths in 2020 alone [1-3]. The incidence is increased among white men and diagnoses often occur in the 7th decade of life [4-6]. The most common type of bladder cancer is urothelial carcinoma (UC), formerly referred to as transitional cell carcinoma. Less than 10% of cases of UC originate in the upper urinary tract, which includes the renal calyces, renal pelvis, and ureters [7-9]. Common risk factors for upper tract UC (UTUC) include smoking and occupational exposures, as well as hereditary nonpolyposis colorectal syndrome (HNPCC or Lynch syndrome) and dietary intake of aristolochic acid [10,11].

Since 2016, the U.S. Food & Drug Administration (FDA) has approved multiple agents targeting the immune pathway. Programmed cell death 1 (PD-1) is a receptor expressed on host immune cells [12]. Tumor cells can downregulate the immune response by expressing programmed deathligand 1 (PD-L1), which leads to the inhibition of cytokine release and T-cell clonal expansion [13,14]. Inhibiting this pathway with antibodies targeting PD-1 and PD-L1 has demonstrated activation of robust antitumor responses against several solid tumors, including UC. Given the success of these immune checkpoint inhibitors (ICIs) in metastatic UC (mUC), there has been a growing interest in incorporating checkpoint blockade into earlier stages of UC. Researchers are also investigating anti-PD-1/PD-L1 ICIs in combination with anti-cytotoxic T-lymphocyte-associated antigen-4 (CLTA-4) ICIs, various chemotherapy regimens, and radiotherapy regimens to enhance therapeutic strategies. In this review, we discuss notable recent and ongoing phase 2 and 3 immunotherapy clinical trials in a) mUC, b) muscle-invasive bladder cancer (MIBC), and c) non-muscle invasive bladder cancer (NMIBC).

First-line Immunotherapy in Metastatic UC

Preferred first-line treatment of mUC in cisplatineligible patients includes chemotherapy with gemcitabine and cisplatin or dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) [15-17]. For cisplatinineligible patients, pembrolizumab and atezolizumab are currently FDA-approved as first-line agents for those with tumors with high PD-L1 expression, or who are ineligible for all platinum-based chemotherapies regardless of PDL1 expression [18].

Accelerated approval of pembrolizumab for first-line mUC treatment was a result of KEYNOTE-052, a single-arm, phase II study of cisplatin-ineligible patients with mUC who were administered intravenous pembrolizumab every three weeks. A favorable objective response rate (ORR) and an even greater response in high PD-L1 patients led to accelerated FDA approval. Updated long-term outcomes are shown in Table 1. Approximately 20% of patients had treatment-related adverse events of grade 3 or greater, most commonly fatigue and colitis [19]. With these encouraging results, a subsequent phase III trial, KEYNOTE-361, was undertaken to compare pembrolizumab with or without chemotherapy to chemotherapy alone. Preliminary data demonstrated reduced survival among low PD-L1 expressors on pembrolizumab monotherapy compared to those on chemotherapy. Due to this, the FDA revised the initial indication for first-line pembrolizumab to include a requirement for high PD-L1 expression for cisplatinineligible patients [18]. Recently, investigators announced that the study did not meet its primary endpoints of a statistically significant improvement in overall survival (OS) and progression free survival (PFS) in the combination group relative to chemotherapy alone [20]. As this data is pending presentation, interpretation of these findings should be limited.

Study Phase Population (Patients) Intervention(s) Responses (%) Survival (months)
ORR: 28.6% (95% CI 24.1-
CR: 8.9%
High PD-L1 group
ORR: 47.3% (95% CI 37.7-
Median OS: 11.3 months (95%
CI 9.7-13.1 months)
PFS: 2.2 months (95% CI 2.1-
3.4 months)
High PD-L1 group Median OS: 18.5 months
(95% CI 12.2-28.5 months)
Pembrolizumab, Pembrolizumab + cisplatin/carboplatin + gemcitabine  
No statistically significant improvement in OS or PFS in the combined group relative to chemotherapy alone
IMvigor210 (Cohort 1)
Updated ORR: 24% (95% CI
Updated CR: 8%
High PD-L1 group
Original ORR: 28% (95% CI
Updated Median OS: 16.3 months (95% CI 10.4-24.5
Original PFS: 2.7 months (95% CI 2.1-4.2 months)
Atezolizumab, Atezolizumab + cisplatin/carboplatin + gemcitabine
Combination: 47% (95% CI
CR: 13%
Chemotherapy: 44% (95%
CI 39-49%)
CR: 7%
Median OS
Combination: 16 months
(95% CI 13.9-18.9 months)
Chemotherapy: 13.4 months
(95% CI 12.0-15.2 months)
Median PFS Combination: 8.2 months
(95% CI 6.5-8.3)
Chemotherapy: 6.3 months
(95% CI 6.2-7.0)

HR: Hazard Ratio; PFS: Progression Free Survival; ORR: Overall Response Rate; OS: Overall Survival

Table 1: FDA Approved First-line ICIs for mUC.

Results from phase II and phase III trials examining the use of atezolizumab as a first-line agent have been encouraging. IMvigor210 (Cohort 1) is a single-arm, phase II study of cisplatin-ineligible patients with mUC given intravenous atezolizumab every 21 days. As shown in Table 1, both IMvigor210 and KEYNOTE-052 show similar ORR for all patients and respectively higher ORR for those with high PD-L1 expression [21]. Similar to KEYNOTE-052, original IMvigor210 Cohort 1 data show that 16% of patients experienced grade 3 or 4 treatment-related adverse events including fatigue and transaminitis [22]. Preliminary data from IMvigor130, a three-arm phase III trial comparing atezolizumab with or without chemotherapy to chemotherapy alone, has also demonstrated a survival reduction among low PD-L1 expressors on atezolizumab monotherapy relative to chemotherapy. This led to a similar restriction for atezolizumab monotherapy, as was previously noted for pembrolizumab monotherapy, to only high PD-L1 expressors. Recently published IMvigor130 results demonstrated prolonged PFS with combination atezolizumab and chemotherapy of 8.2 months versus 6.3 months with chemotherapy alone. This prolongation of PFS is unique to atezolizumab, as KEYNOTE-361 did not show prolonged PFS for pembrolizumab per trial investigator announcement, as previously discussed [20,23]. While a PFS prolongation of approximately 2 months may be seen as providing marginal benefit, combination of atezolizumab and chemotherapy also showed nearly twice the complete response rate relative to chemotherapy alone (13% versus 7%, respectively) with similar safety profiles. With these encouraging results, clinicians should closely examine ongoing atezolizumab trial data for treatment consideration in appropriate patient populations.

There are many ongoing studies for first-line immunotherapy in mUC as shown in Table 2. This includes two phase III studies: LEAP-011 and NILE. LEAP-011 is investigating pembrolizumab and lenvatinib, a multiple tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), and platelet-derived growth factor receptor (PDGFR) [24]. In contrast, NILE includes two ICIs, durvalumab and tremelimumab, an anti-CTLA-4 antibody [25]. Phase II studies for first-line immunotherapy currently include the agents that have already gained FDA approval as second-line treatments, namely nivolumab, avelumab, and durvalumab. There are also multiple phase II studies of combination treatments, which are discussed later. This rapidly advancing field warrants frequent updates on trials and their results.

Intervention(s) Phase Estimated Enrollment (Patients) Estimated Study Date completion Primary Endpoint
NCT03390595 Avelumab + carboplatin + gemcitabine II 85 2020 ORR
NCT03324282 (GCISAVE) Avelumab + cisplatin + gemcitabine II 90 2022 ORR
NCT03682068 (NILE) Durvalumab + cisplatin/ carboplatin + gemcitabine, Durvalumab + Tremelimumab
+ cisplatin/carboplatin + gemcitabine
III 885 2022 PFS OS
NCT03459846 (BAYOU) Durvalumab, Durvalumab + Olaparib II 154 2021 PFS
NCT03451331 Nivolumab + carboplatin/ oxaliplatin + gemcitabine II 48 2022 ORR
NCT03785925 (PIVOT-10) Nivolumab + Bempegaldesleukin II 190 2022 ORR
Nivolumab + Ipilimumab, Nivolumab + gemcitabine + cisplatin III 1290 2024 OS PFS
NCT03898180 (LEAP-011) Pembrolizumab, Pembrolizumab
+ Lenvatinib
III 694 2022 PFS, OS
NCT03534804 (PemCab) Pembrolizumab + Cabozantinib II 39 2023 ORR
NCT03272217 Atezolizumab + Bevacizumab II 70 2021 OS
NCT03473756 Atezolizumab, Atezolizumab + Rogaratinib I and II 210 2024 PFS
NCT03093922 Atezolizumab + gemcitabine + cisplatin II 74 2021 ORR

PFS: Progression Free Survival; ORR: Overall Response Rate; OS: Overall Survival

Table 2: Distribution of demographics, behavioral factors, and comorbidities by deceased status (n=4641).

Second-line and Subsequent-line Immunotherapy in Metastatic UC

ICIs were first approved in mUC as second-line therapies in the post-platinum setting (Table 3). Atezolizumab was approved due to IMvigor210 (Cohort 2), a phase II trial of atezolizumab in progressed mUC that demonstrated an improved ORR relative to a historical ORR of 10% for secondline chemotherapy and a marked improvement in ORR and median OS among high PD-L1 expressors [21,26]. Despite these positive findings, a phase III trial, IMvigor211, did not show a statistically significant improvement in median OS relative to chemotherapy [27]. However, atezolizumab treatment led to fewer treatment-related adverse events relative to chemotherapy at 20% versus 43%, respectively. Following the results of IMvigor211, the second-line indication for atezolizumab was withdrawn in March 2021 [28]. IMvigor130, which studies atezolizumab in the firstline setting, will continue until final analysis. Second-line pembrolizumab approval followed KEYNOTE-045, a phase III trial comparing pembrolizumab with chemotherapy consisting of paclitaxel, docetaxel, or vinflunine [2930]. The pembrolizumab group not only had greater OS, but also fewer treatment-related adverse events of 62% versus 90.6% in the chemotherapy group.

IMvigor210 (Cohort 2) II 310 Atezolizumab Updated ORR: 16% (95%
CI 13-21%)
CR: 7% High PD-L1 group Original ORR: 26% (95%
CI 18%-36%)
Updated Median OS: 7.9 months (95% CI 6.7-9.3 months) High PD-L1 group Original Median OS: 11.4
months (95% CI 9-NE months)
IMvigor211 III 931 Atezolizumab, docetaxel or paclitaxel or vinflunine ORR
Atezolizumab: 13.4% (10.5-
13.4% (10.5-16.9%) High PD-L1 group ORR
Atezolizumab: 23% (95%
CI 15.6-31.9%)
Chemotherapy: 21.6% (95%
CI 14.5-30.2%)
Median OS
Atezolizumab: 8.6 months (95%
CI 7.8-9.6 months)
Chemotherapy: 8.0 months
(95% CI 7.2-8.6 months) High PD-L1 group Median OS Atezolizumab:
11.1 months (95% CI 8.6-15.5
Chemotherapy: 10·6 months (95% CI 8.4-12.2 months)
KEYNOTE-045 III 542 Pembrolizumab, docetaxel or paclitaxel or vinflunine Updated ORR Pembrolizumab: 21.1%
Chemotherapy: 11.0%
Updated Median OS Pembrolizumab: 10.1 months
Chemotherapy: 7.2 months Updated Median PFS Pembrolizumab: 2.1 months
Chemotherapy: 3.3 months
CheckMate275 II 265 Nivolumab ORR: 19.6% (95% CI 15.0-
Median OS: 8.74 months (95% CI 6.05 -NE months
NCT01693562 I/II 191 Durvalumab ORR: 17.8% (95% CI
Median OS: 18.2 months (95% CI 8.1-NE months)
DANUBE III 1126 Durvalumab, Durvalumab + Tremelimumab ORR
Durvalumab + Tremelimumab: 36%
Chemotherapy: 49% High PD-L1 group ORR
Durvalumab: 28%
Chemotherapy: 48%
Median OS
Durvalumab + Tremelimumab:
15.1 months (13.1-18.0 months) Chemotherapy: 12.1 months (10.9-14.0 months) High PD-L1 group Median OS
Durvalumab: 14.4 months (10.4-
17.3 months) Chemotherapy: 12.1 months (10.4-15.0 months)
(JAVELIN Solid Tumor)
I 161 Avelumab ORR: 17% (95% CI 11-24%) Median OS: 6.5 months (95%
CI 4.8–9.5 months)
Study Phase Population (Patients) Intervention(s) Responses (%) Survival (months)

PFS: Progression Free Survival; ORR: Overall Response Rate; OS: Overall Survival

Table 3: FDA Approved Second-line ICIs for mUC.

While only pembrolizumab and atezolizumab are currently FDA approved as both first- and second-line agents, three other ICIs are approved as second-line agents: nivolumab, durvalumab, and avelumab (Table 3).

Approval for nivolumab was based on CheckMate275, a single-arm phase II study of nivolumab that demonstrated an ORR of 19.6% (95% CI 15.0-24.9%), similar to the ORR in IMvigor210 of 16% (95% CI 13-21%). Comparable to IMvigor210, CheckMate275 demonstrated grade 3 to 4 treatment-related adverse events in 18% of patients, most commonly fatigue and diarrhea [31]. Durvalumab was FDA approved based on a phase I/II study with a similar ORR to other second-line ICIs [32]. Grade 3 to 4 treatment-related adverse events occurred in 6.8% of patients. Subsequently, the results of DANUBE, a firstline phase III trial, did not reach its coprimary endpoints of OS in patients treated with combined durvalumab plus tremelimumab compared to chemotherapy and OS in high PD-L1 expressors who received durvalumab alone compared to chemotherapy [33]. In February 2021, the second-line indication for durvalumab was withdrawn [34]. Avelumab was approved based on a phase I trial with pooled results from two cohorts of patients in the JAVELIN Solid Tumor study, which displayed a similar ORR to the above ICIs. Grade 3 to 4 treatment-related adverse events occurred in 8% of patients [35]. Recently reported, in patients without progression after four to six cycles of platinum based chemotherapy, avelumab maintenance therapy has been found to improve OS compared to supportive care based on an interim analysis of JAVELIN Bladder 100, an ongoing phase III study of avelumab with supportive care versus supportive care alone [36]. Median OS on avelumab was 21.4 months versus 14.3 months on supportive care (HR 0.69, 95% CI 0.56 to 0.86, 1-sided p=0.0005). Among high PD-L1 expressors, the median OS was not reached on avelumab versus 17.1 months on supportive care (HR 0.56, 95% CI 0.40 to 0.79, 1-sided p=0.0003). Grade 3 or greater adverse events occurred in 47.4% of avelumab patients versus 25.2% of supportive care treated patients. Based on these results, avelumab has also been FDA approved for post-platinum maintenance therapy in mUC. In a phase II study, NCT02500121, comparing maintenance pembrolizumab and placebo in patients with mUC demonstrating at least stable disease on platinum-based first-line chemotherapy, pembrolizumab showed a greater objective response (23% versus 10%), PFS (5.4 months versus 3.0 months), and median OS (22 months versus 18.7 months) compared to placebo, further supporting the role of maintenance immunotherapy in mUC [37].

With multiple FDA approved second-line ICIs, ongoing trials with ICI combination regimens are underway as shown in Table 4. One phase III study, NCT03390504, is included in this group as one treatment arm is given pembrolizumab [38]. However, the focus of this study is erdafitinib, a FGFR inhibitor. Similar to this study and given the rapid expansion of this field, many of the second-line trials focus on experimental medications in combination with ICIs, as discussed as follows.

Intervention(s) Phase Estimated Enrollment (patients) Estimated Study Date completion Primary Endpoint
NCT04004442 (COAXIN) Avelumab + AVB-S6-500 II 31 2022 ORR
NCT03744793 Avelumab + Pemetrexed II 25 2021 ORR
NCT03891238 (ARIES) Avelumab II 67 2021 Efficacy Endpoints OS
NCT04064190 Durvalumab + Vactosertib II 48 2022 ORR
NCT03871036 (ICRA) Tremelimumab, Tremelimumab + paclitaxel, Tremelimumab + Durvalumab
+ paclitaxel
I and II 50 2023 ORR
NCT03824691 (ARCADIA) Durvalumab + Cabozantinib II 122 2023 OS
NCT03606174 Nivolumab + Sitravatinib, Pembrolizumab + Sitravatinib
+ Enfortumab vedotin
II 330 2021 ORR
NCT03980041 (MARIO-275) Nivolumab, Nivolumab + IPI- 549 II 160 2022 ORR
NCT02387996 Nivolumab II 386 2021 ORR
NCT03390504 Pembrolizumab, Erdafitinib, docetaxel or vinflunine III 631 2023 OS
NCT02717156 Pembrolizumab + EphB4-HSA II 60 2021 OS
NCT02500121 Pembrolizumab II 108 2020 PFS
NCT03263039 (RESPONDER) Pembrolizumab II 80 2020 Biomarkers in clinical responders
NCT02581982 Pembrolizumab + paclitaxel II 29 2021 ORR
NCT03854474 Pembrolizumab + Tazemetostat I and II 30 2020 Safety
NCT02500121 Pembrolizumab II 108 2020 PFS
NCT03737123 Atezolizumab + carboplatin + gemcitabine or Atezolizumab + docetaxel II 33 2022 PFS
NCT04045613 (FIDES-02) Derazantinib + Atezolizumab, Derazantinib I and II 303 2022 ORR
NCT03513952 Atezolizumab + CYT107 II 54 2020 ORR
NCT03237780 Atezolizumab + Eribulin mesylate II 78 2021 ORR
NCT03179943 Atezolizumab + Guadecitabine II 53 2022 ORR

PFS: Progression Free Survival; ORR: Overall Response Rate; OS: Overall Survival

Table 4: Ongoing Studies of Second-line Immunotherapy for mUC clinical trial information obtained from ClinicalTrials.gov.

Combination Immunotherapy in Metastatic UC

Many combinatorial studies are investigating ICIs with growth factor inhibitors, such as PemCab, a first-line, phase II, single group study combining pembrolizumab and cabozantinib, a multiple TKI [39]. Other first-line studies are also examining ICIs in combination with growth factor inhibitors, such as LEAP-011 with lenvatinib, NCT03272217 with vascular endothelial growth factor (VEGF) inhibitor bevacizumab, and NCT03473756 with FGFR inhibitor rogaratinib [24,40,41]. Second-line studies with ICI and growth factor inhibitor combinations are listed in Table 4. One recently published second-line, phase II study, RAPID CHECK, comparing combination pembrolizumab and acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, versus pembrolizumab alone in platinum resistant mUC found no significant improvement in OS, PFS, or ORR with combination therapy and also showed higher adverse event rates. Despite these results, combination therapy resulted in increased CD8+ T-cell proliferation [42]. Further studies will be needed to determine if this immune stimulation results in increased tumor infiltration. Overall, the goal of these studies is to determine if targeting two different mechanisms of oncogenesis can provide a benefit over targeting these mechanisms in exclusion.

Combination studies are also seen with two ICIs together as well, all of which currently feature a PD-1/PD-L1 inhibitor combined with a CTLA-4 inhibitor. First-line studies include NCT03682068 (NILE) with durvalumab and tremelimumab, and NCT03036098 (CheckMate901) with nivolumab and ipilimumab [25,43]. CheckMate901 follows encouraging results from a phase I/II post-platinum trial of nivolumab with ipilimumab that demonstrated a greater ORR of 26.9% and 38.0% in the combination groups of two different dosage regimens relative to an ORR of 25.6% with nivolumab alone, while also maintaining comparable safety profiles [44]. One second-line study NCT03871036 (ICRA) includes durvalumab and tremelimumab [45].

Expansion beyond these treatment classes is also occurring rapidly, with novel medications of different mechanisms of action being examined with ICIs. First-line studies include NCT03288545 (EV-103), NCT03459846 (BAYOU), and NCT03785925 (PIVOT-10) [46-48]. Encouraging preliminary results were recently presented for EV-103 which is investigating first-line enfortumab vedotin, an antibody-drug conjugate targeting a cancer-associated cell surface protein nectin-4, with pembrolizumab in cisplatinineligible mUC. EV-103 demonstrated an ORR of 73.3% (95% CI 58.1-85.4%) overall and an ORR of 78.6% in high PD-L1 expressors [46]. Second-line studies in this category are listed in Table 4. As this field continues to grow, further unique mechanisms of oncogenic inhibition will continue to be explored.

Despite advances in the field, not all combination therapies result in a favorable outcome. KEYNOTE-672 investigated pembrolizumab monotherapy versus pembrolizumab with epacadostat, an indoleamine 2,3-deioxygenase 1 (IDO1) inhibitor [49]. While preliminary data shows an improved ORR with combination therapy of 31.8% (95% CI 22.46 to 55.24%) versus 24.5% (95% CI 15.33 to 43.67%) with pembrolizumab monotherapy, there is a higher all-cause mortality of 29.55% versus 20.41% respectively. As these preliminary results have not yet been discussed in a peer reviewed publication, interpretation of these findings should be limited. Concurrent with these preliminary results is KEYNOTE-252, which investigates the same drug combination but in metastatic melanoma, and showed no improvement in PFS or OS when compared to pembrolizumab alone [50]. Thus, novel therapies must be carefully considered for inclusion in upcoming trials.

Muscle-Invasive Bladder Urothelial Carcinoma

Patients diagnosed with non-metastatic MIBC (pT2 or greater) are initially assessed for surgical candidacy. Candidates for surgery are recommended to undergo neoadjuvant chemotherapy followed by radical cystectomy and pelvic lymph node dissection [51-53]. Cisplatin is the cornerstone of neoadjuvant chemotherapy [52]. However, up to 50% of UC patients are cisplatin-ineligible due to renal insufficiency, peripheral neuropathy, and other comorbidities [54]. Patients who are at significant risk of disease progression are considered for concurrent chemoradiation therapy [55]. Taken together, this underscores the importance of alternative treatments options for MIBC [54,56,57].

Given the success of neoadjuvant cisplatin in MIBC, many ICI studies utilize cisplatin in the investigational drug regimen. Numerous trials combine gemcitabinecisplatin with ICIs such as nivolumab (BLASST-1 NCT03294304), pembrolizumab (NCT02690558, HCRN GU14-188 NCT02365766), avelumab (AURA NCT03674424), and investigational PD-1 antibody toripalimab (NCT04099589) [58-60]. BLASST-1 results report positive safety and efficacy data, including 66% pathologic downstaging (≤ pT1N0) [61]. In HCRN GU14- 188, pembrolizumab and gemcitabine-cisplatin led to a 61.1% pathologic downstaging and 44.4% pathologic complete response (pCR) rate (pT0) in cisplatin-eligible patients [62].

Despite neoadjuvant cisplatin being the gold standard, problems with eligibility due to risks of this regimen have led to numerous trials designed to address the cisplatin-ineligible patient population. Neoadjuvant atezolizumab (ABACUS, NCT02662309, NCT02451423) and pembrolizumab (PANDORE, NCT03212651) are being studied in single-arm phase 2 trials. In the ABACUS trial, patients received two courses of atezolizumab prior to radical cystectomy resulting in a 31% pCR rate [63]. HCRN GU14-188 included a cisplatin-ineligible arm that received pembrolizumab and gemcitabine [64]. Interim results show 51.6% pathologic downstaging and 45.2% pCR rate. In both arms of HCRN GU14-188, response rates did not correlate with PD-L1 scores.

Neoadjuvant pembrolizumab monotherapy was recently studied in multiple single-arm phase 2 studies (PURE- 01, NCT03319745). In PURE-01, patients received three courses of pembrolizumab prior to radical cystectomy [65,66]. There was a 39% pCR rate and 56% pathologic downstaging, further supporting the efficacy of ICIs in the neoadjuvant setting. The surgical safety of radical cystectomy and pelvic lymph node dissection following the administration of pembrolizumab was also shown in a separate report where there were no perioperative mortalities at 90 days and 34% of patients experienced high-grade (≥ 3a) complications, which is comparable to radical cystectomy following chemotherapy [67]. Both ABACUS and PURE-01 (NCT02736266) report promising analyses with candidate biomarkers. However, randomized controlled trials are needed to strengthen findings from these studies [63,68].

Ongoing neoadjuvant approaches employ a combination of ICIs. Durvalumab is being studied in combination with anti-CTLA-4 antibody tremelimumab (DUTRENEO NCT03472274), nivolumab with anti-CTLA-4 antibody ipilimumab (NCT03520491), and nivolumab with CD137 agonist antibody urelumab (NCT02845323) [69]. In DUTRENEO, patients with tumors that had a high pro-inflammatory interferon-gamma signature (tumor immune score, TIS) were randomized to durvalumab with tremelimumab versus chemotherapy, and patients with low TIS tumors received chemotherapy, resulting in pCR rates of 34.8%, 36.4%, and 68.8%, respectively). Although TIS failed to predict response, patients with high PD-L1 expression showed a greater response compared to patients with low PD-L1 expression (pCR = 57.1% and 14.3%, respectively) [70]. NEMIO is a phase 1/2 study investigating durvalumab and ddMVAC with or without tremelimumab (NCT03549715) [71]. Other studies combine neoadjuvant ICI with investigational or off-label agents, including pembrolizumab with investigational entinostat (NCT03978624), a selective class I histone deacetylase inhibitor, and epacadostat (PECULIAR NCT03832673); and atezolizumab with cabozantinib (NCT04289779), a small molecule TKI [72]. Promising preliminary data offers the possibility of expanding the neoadjuvant repertoire for MIBC.

Data supporting the use of adjuvant immunotherapy is limited, however some studies have shown benefit [73,74]. There are multiple randomized phase 3 studies comparing adjuvant ICI use to observation in MIBC at high-risk for recurrence using atezolizumab (IMvigor010 NCT02450331), pembrolizumab (AMBASSADOR NCT03244384), and nivolumab (CheckMate 274 NCT02632409), as well as a randomized phase 2 study in MIBC using adjuvant durvalumab (NCT03768570) [75]. These studies include some patients who have had chemotherapy prior to surgery. IMvigor010 did not reach its primary endpoint of disease-free survival (DFS) for patients treated with adjuvant atezolizumab compared to control patients (median DFS = 19.4 months and 16.6 months, respectively). Furthermore, there are multiple randomized phase 3 studies employing ICI use perioperatively, both before and after radical cystectomy, using pembrolizumab (KEYNOTE-905 NCT03924895), pembrolizumab with gemcitabine-cisplatin (KEYNOTE-866, NCT03924856), and durvalumab with gemcitabine-cisplatin (NIAGARA NCT03732677), nivolumab with bempegaldesleukin (NCT04209114), an investigational CD122-preferential IL-2 pathway agonist, and nivolumab with linrodostat, an IDO1 inhibitor, and chemotherapy (ENERGIZE NCT03661320) [76-79].

Given the number of patients who are ineligible or who chose not to undergo surgery, there is an ongoing interest in bladder-sparing approaches. CRIMI is a phase 1/2 study investigating nivolumab and ipilimumab with mitomycin, capecitabine, and radiotherapy in two weightbased dosing arms versus fixed dose nivolumab with chemoradiotherapy (NCT03844256). Ongoing phase 2 studies include durvalumab with tremelimumab and radiotherapy (IMMUNOPRESERVE NCT03702179), nivolumab with gemcitabine-cisplatin (NCT03558087), and atezolizumab with radiotherapy (NCT04186013) [80]. Details of phase 2 and 3 bladder-sparing studies employing ICI with chemoradiotherapy are in Table 5 [80-84].

Intervention(s) Phase Estimated Enrollment (patients) Estimated Study Completion Date Primary Endpoint UTUC
Included in Enrollment
NCT02736266 (PURE-01) Pembrolizumab II 90 2019 pCR No
NCT03319745 Pembrolizumab II 20 2020 Toxicity No
NCT02662309 (ABACUS) Atezolizumab II 96 2020 pCR No
NCT02451423a Atezolizumab II 42 2021 Change in CD3+ T-cell count, pCR No
NCT03212651 (PANDORE) Pembrolizumab II 41 2019 pCR No
NCT03294304 (BLASST-1) Nivolumab, Gemcitabine- Cisplatin II 43 2020 PaR No
NCT02690558 Pembrolizumab, Gemcitabine-Cisplatin II 39 2025 Pathologic downstaging No
NCT02365766 (HCRN GU14-188) Pembrolizumab, Gemcitabine-Cisplatin I/II 83 2021 Safety, PaIR Yes
NCT03674424 (AURA) Avelumab, Chemotherapy II 166 2022 pCR Yes
NCT04099589 Toripalimab, Gemcitabine- Cisplatin II 60 2022 pCR Yes
NCT03472274 (DUTRENEO) Durvalumab, Tremelimumab II 99 2022 Antitumor activity Yes
NCT03520491 Nivolumab, Ipilimumab II 45 2021 Treatment adherence/Toxicity No
NCT02845323 Nivolumab, Urelumab II 44 2021 CD8+ T-cell density at cystectomy No
NCT03549715 (NEMIO) Durvalumab, Tremelimumab, ddMVAC I/II 120 2024 Toxicity, pCR No
NCT03978624 Pembrolizumab, Entinostat II 20 2022 CD8+ T-cell immune 37-gene signature No
NCT03832673 (PECULIAR) Pembrolizumab, Epacadostat II 38 2020 pCR No
NCT04289779 Atezolizumab, Cabozantinib II 42 2023 pCR No
NCT02450331 (IMvigor010) Atezolizumab III 809 2022 DFS Yes
NCT03244384 (AMBASSADOR) Pembrolizumab III 739 2025 OS, DFS Yes
NCT02632409 (CheckMate 274) Nivolumab III 700 2026 DFS Yes
NCT03768570 Durvalumab II 238 2024 DFS No
NCT03924895 (KEYNOTE-905) Pembrolizumab III 610 2026 pCR, EFS No
NCT03924856 (KEYNOTE-866) Pembrolizumab, Gemcitabine-Cisplatin III 790 2025 pCR, EFS No
NCT03732677 (NIAGARA) Durvalumab, Gemcitabine-Cisplatin III 1050 2025 pCR, EFS No
NCT04209114 Nivolumab, NKTR-214 III 540 2027 pCR, EFS No
NCT03661320 Nivolumab, Linrodostat, Chemotherapy III 1200 2026 pCR, EFS No
NCT03844256 (CRIMI) Nivolumab, Ipilimumab, Mitomycin, Capecitabine, Radiotherapy I/II 50 2023 Toxicity, DLT, DFS No
NCT03702179 (IMMUNOPRESERVE) Durvalumab, Tremelimumab, Radiotherapy II 32 2022 PaR No
NCT03558087 Nivolumab, Gemcitabine- Cisplatin II 63 2022 CR No
NCT04186013 Atezolizumab, Radiotherapy II 39 2027 pCR No
NCT04241185 (KEYNOTE-992) Pembrolizumab, Chemotherapy, Radiotherapy III 636 2027 Bladder Intact- EFS No
NCT02662062 (ANZUP 1502) Pembrolizumab, Cisplatin, Radiotherapy II 30 2024 Toxicity No
NCT02621151 Pembrolizumab, Gemcitabine, Radiotherapy II 54 2026 Bladder Intact- DFS No
NCT03775265 (SWOG/ NRT-1806) Atezolizumab, Radio- therapy, Gemcitabine or Cisplatin or Fluorouracil, Mitomycin III 475 2025 Bladder Intact- EFS No
NCT03617913 Avelumab, Radiotherapy, Fluorouracil, Mitomycin or Cisplatin II 2 2025 CR No
NCT03171025 (NEXT) Nivolumab, Radiotherapy, Chemotherapy II 28 2024 FFS No
NCT03993249 Nivolumab, Radiotherapy, Chemotherapy II 78 2021 Locoregional control rate No

pCR: Pathologic Complete Response; PaIR: Rate of pathologic muscle Invasive Response; PaR: Pathologic Response rate; DSF: Disease Free Survival; OS: Overall Survival; DLT: Dose-limiting Toxicity; EFS: Event-free Survival; CR: Complete Response; FFS: Failure-free Survival
aEnrollment includes NMIBC and MIBC patients. See Table 6 for more detail.

Table 5: Recent or ongoing phase II and III muscle-invasive urothelial carcinoma clinical trial information obtained from ClinicalTrials.gov.

Non-Muscle Invasive Bladder Urothelial Carcinoma

Non-muscle invasive bladder cancer (NMIBC; Ta, T1, and Tis) is treated with transurethral resection of the bladder tumor (TURBT) and intravesical chemotherapy or immunotherapy [15,85]. In patients with intermediate or high-risk NMIBC, intravesical Bacillus Calmette-Guérin (BCG) can be used as local immunotherapy [86,87]. However, after BCG therapy, as many as 80% of NMIBC patients will experience disease recurrence and up to 45% will have disease progression [88].

The success of checkpoint blockade in mUC has led to the development of numerous studies incorporating ICIs in the treatment of BCG-refractory high-risk NMIBC. Pembrolizumab was recently investigated in the single-arm phase 2 KEYNOTE-057 study for patients who were unfit or unwilling to undergo radical cystectomy (NCT02625961) [89,90]. Patients received pembrolizumab every 3 weeks for up to 24 months or until unacceptable toxicity, persistent or recurrent high-risk NMIBC, or progressive disease. The complete response (CR) rate was 41% at 3 months and the median duration of response in responders was 16.2 months. Pembrolizumab was discontinued in 11% of patients, most commonly due to pneumonitis. On January 8, 2020, the FDA approved pembrolizumab for the treatment of patients with BCGrefractory high-risk NMIBC with carcinoma in situ (CIS) with or without papillary tumors who are unfit/ unwilling to undergo cystectomy [91]. Similar phase 2 studies with atezolizumab (SWOG S1605 NCT02844816, NCT02451423), durvalumab (NCT02901548) are currently ongoing [92]. SWOG 1605 focused on a subset of patients with CIS showing that 41% and 26% of patients achieved complete remission at 3 and 6 months, respectively [93]. NCT02451423 employs sequentially increasing doselevel cohorts by enrollment. Although ICIs are typically administered intravenously, durvalumab is being investigated with intravesical administration in a phase 2 study to minimize systemic toxicity (NCT03759496).

Several studies are employing multi-therapeutic approaches with ICIs in the setting of BCG-refractory high-risk NMIBC. Several ICIs are being investigated in combination with BCG, chemotherapy, or radiotherapy in phase I/II, II, and III studies described in Table 6 [94,95]. Nivolumab is being studied with or without linrodostat, and with or without BCG in a randomized phase 2 study (CheckMate 9UT NCT03519256) [96,97]. Pembrolizumab is being studied with CG0070, an oncolytic serotype-5 adenovirus, in a single-arm phase 2 study (NCT04387461). Durvalumab is being studied with S-488210/S-488211, a 5-peptide cancer vaccine, in a single-arm phase 1/2 study (DURANCE NCT04106115).

Given recent reports of shortages of BCG availability in the USA, many researchers are interested in using ICIs in the first-line setting for high-risk NMIBC [98-101]. ALBAN is a phase 3 randomized trial comparing atezolizumab with BCG and BCG monotherapy in BCG-naive patients (NCT03799835) [102]. Similarly, POTOMAC is a phase 3 randomized trial comparing durvalumab with BCG induction/maintenance dual-therapy, durvalumab with BCG induction dual-therapy, and BCG induction/ maintenance dual-therapy in BCG-naive patients (NCT03528694) [103]. Pembrolizumab monotherapy is being studied in a single-arm phase 2 study in BCG-naive patients (NCT03504163). Details of NMIBC trials are summarized in Table 6.

ClincailTrials.gov Identifier Intervention(s) Phase Estimated Enrollment (Patients) Estimated Study Completion
Primary Endpoint
BCG unresponsive/refractory
NCT02625961 (KEYNOTE-057) Pembrolizumab II 260 2023 CR, DFS
NCT02844816 (SWOG S1605) Atezolizumab II 202 2021 CR, EFS
NCT02451423a Atezolizumab II 42 2021 Change in CD3+ T-cell count, pCR
NCT02901548 Durvalumab II 34 2021 CR
NCT03759496 Durvalumab II 39 2021 MTD, HGRF
(ABC Trial)
Avelumab, BCG I/II 27 2025 Proportion of patients receiving a complete
induction course
NCT02792192 Atezolizumab, BCG I/II 24 2021 Safety, DLT (BCG), (BCG), MTD/MAD (BCG), CR
NCT03711032 (KEYNOTE-676) Pembrolizumab, BCG III 550 2024 CR
NCT04149574 (CheckMate 7G8) Nivolumab, BCG III 700 2030 EFS
NCT04164082 Pembrolizumab, Gemcitabine II 163 2023 CR, EFS
NCT03950362 (PREVERT) Avelumab, Radiotherapy II 67 2024 High-risk RFS
NCT03317158 (ADAPT-BLADDER) Durvalumab, BCG or Radiotherapy I/II 186 2023 Determine the recommended phase 2 dose, RFS
NCT03519256 (CheckMate 9UT) Nivolumab, Linrodostat, BCG II 358 2026 CR, DOCR (CIS participants)
NCT04387461 Pembrolizumab, CG0070 II 37 2022 CR
NCT04106115 (DURANCE) Durvalumab,
I/II 64 2027 DLT, DFS
NCT03799835 (ALBAN) Atezolizumab, BCG III 614 2028 RFS
NCT03528694 (POTOMAC) Durvalumab, BCG III 975 2024 DFS
NCT03504163 Pembrolizumab II 37 2021 DFS
NCT03345134 Pembrolizumab, BCG II 20 2021 CR

CR: Complete Response; DFS: Disease Free Survival; EFS: Event-free Survival; pCR: Pathologic Complete Response; MTD: Maximum Tolerated Dose; HGFR: High-grade Relapse Free; DLT: Dose-limiting Toxicity; MAD: Maximum Administered Dose,
RFS: Recurrence-free Survival; DOCR: Duration of Complete Response

aEnrollment includes NMIBC and MIBC patients. See Table 5 for more detail.

Table 6: Recent or ongoing phase II and III non-muscle invasive urothelial carcinoma clinical trial information obtained from ClinicalTrials.gov.

Upper-tract Urothelial Carcinoma

UTUC exhibits a higher incidence of invasive disease at the time of diagnosis relative to UC of the bladder [9]. Therefore, UTUC is often treated with nephroureterectomy and adjuvant chemotherapy [104]. For low risk UTUC, nephron-sparing surgery may be considered, while metastatic disease is treated with systemic chemotherapy [51].

There are few ongoing immuno-oncology trials designed for UTUC patients alone. In one single-arm phase 2 study, patients with high-risk UTUC (CIS, Ta, T1) who are unfit or unwilling to undergo a nephroureterectomy receive pembrolizumab and BCG after endoscopic ablation (NCT03345134) [105]. UTUC patients are often permitted to enroll in UC studies where the majority of patients have tumor originating in the bladder. For instance, in IMvigor010, 13% of patients had UTUC, however the results were not reported by disease site [106]. In KEYNOTE-052, 69 out of 370 patients had a primary tumor location in the upper urinary tract. The ORR was 26.1% and 29.3% for UTUC and lower-tract, respectively, and the median OS was 10.8 months and 11.5 months, respectively [19]. In IMvigor210, 33 out of 119 patients had a primary tumor location in the upper urinary tract. The ORR was 39% and 17% for UTUC and lower-tract, respectively [22]. These data support the clinical efficacy of first-line pembrolizumab or atezolizumab for cisplatinineligible locally advanced or metastatic UTUC patients, however further clinical trials are needed.

Regarding second-line ICI therapy in metastatic UTUC patients, limited subgroup analyses have been performed in some of the previously discussed studies. In IMvigor211, a subgroup analysis of 234 high PD-L1 expressors demonstrated that 51 of these patients had UTUC. Among UTUC patients compared to all high PD-L1 expressors, there was a trend towards a less favorable HR for death, although not statistically significant, with atezolizumab treatment relative to chemotherapy at a HR of 0.81 (95% CI 0.59-1.10) among all high PD-L1 expressors, a HR of 1.32 (95% CI 0.50-3.48) among renal primary patients, and a HR of 0.92 (95% CI 0.36-2.34) among ureter primary patients [27]. KEYNOTE-045 supplementary materials note that 38 patients (14.1%) had upper tract primary tumor sites but does not include a subgroup analysis of these patients [29]. CheckMate275 does not specify the proportion of patients with upper tract disease and NCT01693562 does not specify if upper tract patients are included [31,32]. JAVELIN data for avelumab includes a subgroup analysis of 36 upper tract patients out of 161 total patients, and notes a poorer ORR among upper tract patients of 11% versus an ORR of 18% among lower tract patients [35]. Together, these limited findings suggest that patients with primary upper tract disease may have less favorable responses to second-line ICI therapy than lower tract patients and demonstrates the need for further upper tract-specific studies. Metastatic UC trials, as listed in Tables 1-4, either explicitly state that UTUC patients are enrolled, or their enrollment is inferred in studies that do not differentiate by UC site.

The small UTUC sample sizes in these studies likely limit the power for UTUC-specific analyses. This is both a consequence of the lower incidence of UTUC relative to UC originating in the bladder and trial designs, which exclude UTUC patients from enrolling. UTUC-specific studies are an area in need of further contribution.

Immunotherapy Biomarkers in Urothelial Carcinoma

Given the varied response rate to ICIs based on cellular markers, further studies into biomarkers are warranted in the UC population. Improvements in this respect will benefit trial design, treatment selection, and patient counseling. PD-L1 expression is the most frequently used biomarker in clinical trial designs studying ICIs in UC treatment. PD-L1 expression is currently calculated by two different methods. A combined positive score (CPS), which is the percentage of PD-L1 positive cells in a tumor sample, of greater than 10 represents high PDL1 expression [107]. The second criteria for high PD-L1 expression is defined as having a tumor sample with 5% or greater of tumor-infiltrating immune cells (IC) stain positive for PD-L1 [22]. The FDA has approved multiple diagnostic tests to measure PD-L1 expression [108,109]. In a recent meta-analysis of 9 clinical trials comprising 1,436 patients, patients with high PD-L1 expression had significant improvements in ORR relative to low PD-L1 expression. PD-L1 expression was better at predicting ORR for patients treated with atezolizumab, durvalumab, and pembrolizumab, compared to nivolumab and avelumab [110]. Further, PD-L1 expression predicted one-year OS for patients treated with PD-L1 inhibitors, but not PD-1 inhibitors. Further description of the relationship between PD-L1 expression and oncologic outcomes is described above for select trials.

In addition to using PD-L1 expression as a biomarker for ICI therapy responsiveness, other biomarkers such as tumor mutational burden (TMB), DNA damage response (DDR) gene defects, and microsatellite instability (MSI) are being studied as markers to predict susceptibility to ICI therapy. TMB refers to the mutation count per coding region in the genome. IMvigor210 performed a subgroup analysis with TMB and found correlations with both greater response rates and longer OS in patients with higher TMB [111]. One study performed genetic sequencing of patients with ICI treated non-small cell lung cancer and found that TMB and PD-L1 expression are not correlated and are both comparable in predicting responsiveness to ICIs [112]. Further TMB studies are warranted to determine if TMB can serve as an independent and validated biomarker for ICI responsiveness in UC.

Defects in DDR genes have been associated with TMB and are also being investigated for predicting ICI responsiveness. In a study of 60 mUC patients enrolled in various ICI treatment trials, DDR gene deletions and high TMB were both associated with greater response rates and OS. Concordant with the known association between DDR gene defects and TMB, this study found that these biomarkers are not mutually independent. When performing multivariable analyses, DDR defect status was found to be superior to TMB at predicting ICI response based on regression modelling goodness of fit [113]. Thus, DDR defect status should also be investigated concurrently with TMB as a biomarker for ICI responsiveness.

Microsatellite instability, characterized by DNA mismatch repair deficiencies, has also been correlated with TMB and ICI response in UC [114]. Of particular importance given the need for dedicated UTUC analysis, one recent study of 128 UTUC patients found that 28.1% of patients demonstrated MSI [115]. With pembrolizumab FDA approval for progressed metastatic high MSI solid tumors and recent approval for first-line treatment of high MSI metastatic colorectal cancer, further investigation into MSI as a biomarker for UC, and particularly UTUC, should be performed [116,117].

Immune-Related Adverse Events

Given the role that ICIs play in potentiating the immune response to tumor antigens through inhibiting selftolerance, ICIs may also activate the immune response against self-antigens in healthy tissues outside of the tumor microenvironment leading to numerous inflammatory toxicities known as immune-related adverse events (irAEs). These ICI side effects can often substantially differ from cytotoxic chemotherapy side effects. irAEs can potentially affect any organ. The prevalence of irAEs is up to 70% and 90% in patients treated with a PD-1/PD-L1 inhibitor and CTLA-4 inhibitor, respectively, with mild to moderate skin and gastrointestinal irAEs being more common and the rates of grade 3 and 4 toxicities being fairly low [118,119]. Table 7 summarizes irAEs documented during the use of ICIs [120]. Clinical Practice Guidelines published recently by the American Society of Clinical Oncology recommends continuing therapy with close-monitoring for most grade 1 toxicities, whereas subsequently higher grade toxicities may call for suspension of the ICI and in some cases the use of corticosteroids, immunosuppressive therapy (e.g., infliximab), or other interventions [120]. Most patients tolerate immune therapy, and patients with mild side effects often continue therapy with minimal impact on quality of life. The decision to continue therapy or resume therapy following cessation due to irAEs may be influenced by other factors including the patient’s tumor response or biomarker status.

Organ System Documented Toxicities
Skin •Rash/inflammatory dermatitis
•Bullous dermatoses
•Steven-Johnson        syndrome/ toxic epidermal necrolysis
•Drug rash with eosinophilia and
systemic symptoms
Gastrointestinal •Colitis
Lung •Pneumonitis
Endocrine •Primary hypothyroidism
•Primary adrenal insufficiency
Musculoskeletal •Inflammatory arthritis
•Polymyalgia-like syndrome
Renal •Nephritis
Nervous system •Myasthenia gravis
•Guillain-Barré syndrome
•Peripheral neuropathy
•Autonomic neuropathy
•Aseptic meningitis
•Transverse myelitis
Hematologic •Autoimmune hemolytic anemia
•Acquired thrombotic thrombocytopenic purpura
•Hemolytic uremic syndrome
•Aplastic anemia
•Immune thrombocytopenia
•Acquired hemophilia
Cardiovascular •Myocarditis, pericarditis, arrhythmias, impaired ventricular function with heart failure, and vasculitis
•Venous thromboembolism
Ocular •Uveitis/iritis

aDocumented toxicities are not limited to the examples included in Table 7.

Table 7: Documented toxicities of immune checkpoint inhibitors by organ system obtained from the Clinical Practice Guidelines published by the American Society of Clinical Oncology [120].

The prevalence of irAEs is thought to be higher with CTLA- 4 inhibitors compared to PD-1/PD-L1 inhibitors, and highest with combination therapy. In one study, grade 3-4 irAEs were observed in 16.3%, 27.3% and 55.0% of patients taking nivolumab, ipilimumab, and combined nivolumab plus ipilimumab, respectively [121]. Furthermore, toxicity is thought to be driven more by dose for CTLA-4 inhibitors relative to PD-1/PD-L1 inhibitors [122]. irAEs can occur at any time during treatment, including months after treatment cessation [118,119]. Of note, many studies exclude patients with preexisting autoimmune disease, chronic viral infection, organ transplant, etc. These patients are underrepresented in published research and may respond differently, warranting closer follow-up. Most of the published data on irAEs is not specific to patients treated for UC, and patient demographics may differ.

Despite increased acceptance of ICIs, irAEs remain a significant concern. Ultimately, the benefits of ICI therapy must be weighed against the potential toxicity and detriments to quality of life that irAEs may pose. Further research is needed to identify patients at increased risk for irAEs and to better understand the risks and management protocols that best serve patients.

Future Directions and Conclusion

Checkpoint blockade has demonstrated safety and efficacy in numerous trials for mUC and high-risk NMIBC leading to multiple FDA approvals. Although recent withdrawn indications for two second-line agents is disappointing, ICIs continue to show clinical efficacy and safety in many settings. These withdrawals affect the United States, but not Europe. Ongoing studies are investigating ICIs in different MIBC settings, including at the neoadjuvant, adjuvant, perioperative, and bladder-sparing stages. In mUC, studies are investigating ICI in combination with novel chemotherapy and immunotherapy agents. One area of need in ICI studies is an analysis of UTUC patients given complexities in staging and subsequent treatment recommendations. An explanation for why minimal data has been published for UTUC patients is that insufficient UTUC enrollment numbers are reached in UC studies to power a UTUC-specific analysis. Future studies should aim to report safety and efficacy data for UTUC patients independently. Given the increased uptake of ICIs, clinicians must be able to recognize irAEs that may accompany these agents. With many ongoing studies incorporating ICIs and novel biomarkers in a variety of pharmacologic and radiotherapeutic regimens, the treatment landscape of UC is evolving rapidly.

Author Contributions Statement

A.P. and D.I.B. prepared the initial draft. All authors contributed to discussion and reviewed/edited the manuscript.

Conflicts of Interest

The authors have no conflicts of interest.


This work is supported by a grant from the National Cancer Institute (P30CA072720).


1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

2. Yeung C, Dinh T, Lee J. The health economics of bladder cancer: an updated review of the published literature. Pharmacoeconomics. 2014;32(11):1093-104.

3. Noyes K, Singer EA, Messing EM. Healthcare economics of bladder cancer: cost-enhancing and costreducing factors. Curr Opin Urol. 2008;18(5):533-9.

4. Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol. 2017;71(1):96- 108.

5. American Cancer Society. Bladder Cancer Risk Factors 2019 [Available from: https://www.cancer.org/cancer/bladder-cancer/causes-risks-prevention/risk-factors.html.

6. American Cancer Society. Key Statistics for Bladder Cancer 2020 [Available from: https://www.cancer.org/cancer/bladder-cancer/about/key-statistics.html.

7. Tawfiek ER, Bagley DH. Upper-tract transitional cell carcinoma. Urology. 1997;50(3):321-9.

8. Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol. 2000;164(5):1523-5.

9. Raman JD, Messer J, Sielatycki JA, Hollenbeak CS. Incidence and survival of patients with carcinoma of the ureter and renal pelvis in the USA, 1973-2005. BJU Int. 2011;107(7):1059-64.

10. Rouprêt M, Yates DR, Comperat E, Cussenot O. Upper urinary tract urothelial cell carcinomas and other urological malignancies involved in the hereditary nonpolyposis colorectal cancer (lynch syndrome) tumor spectrum. Eur Urol. 2008;54(6):1226-36.

11. Colin P, Koenig P, Ouzzane A, Berthon N, Villers A, Biserte J, et al. Environmental factors involved in carcinogenesis of urothelial cell carcinomas of the upper urinary tract. BJU Int. 2009;104(10):1436-40.

12. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.

13. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027-34.

14. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 2006;27(4):195-201.

15. Flaig TW, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, et al. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020;18(3):329-54.

16. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23(21):4602-8.

17. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, et al. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol. 2000;18(9):1921-7.

18. Suzman DL, Agrawal S, Ning Y, Maher VE, Fernandes LL, Karuri S. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. The Oncologist. 2019;Apr;24(4):563-9.

19. Vuky J, Balar AV, Castellano D, O’Donnell PH, Grivas P, Bellmunt J, et al. Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. J Clin Oncol. 2020;38(23):2658-66.

20. Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma Merck2020 [Available from: https://www.merck.com/ news/merck-provides-update-on-phase-3-keynote- 361-trial-evaluating-keytruda-pembrolizumab-asmonotherapy- and-in-combination-with-chemotherapyin- patients-with-advanced-or-metastatic-urothelial-carc/.

21. Balar AV, Dreicer R, Loriot Y, Perez-Gracia JL, Hoffman-Censits JH, Petrylak DP, et al. Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. J Clin Oncol. 2018;36(15_suppl):4523.

22. Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. The Lancet. 2017;7;389(10064):67-76.

23. Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet Lond Engl. 2020;16;395(10236):1547-57.

24. Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK- 7902-011/E7080-G000-317/ LEAP-011) ClinicalTrials. gov [Available from: https://clinicaltrials.gov/ct2/show/ NCT03898180.

25. Gomez-Munoz A, Kong JY, Salh B, Steinbrecher UP. Ceramide-1-phosphate blocks apoptosis through inhibition of acid sphingomyelinase in macrophages. Journal of Lipid Research. 2004 Jan 1;45(1):99-105.

26. Rosenberg JE, Hoffman-Censits J, Powles T, Heijden MS, Balar AV, Necchi A. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet Lond Engl. 2016;7;387(10031):1909-20.

27. Powles T, Durán I, der HMS, Loriot Y, Vogelzang NJ, Giorgi UD. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, openlabel, phase 3 randomised controlled trial. The Lancet. 2018;Feb 24;391(10122):748-57.

28. Roche. Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer 2021 [Available from: https://www.roche.com/media/releases/med-cor-2021-03-08.htm.

29. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376(11):1015-26.

30. Necchi A, Fradet Y, Bellmunt J, de Wit R, Lee JL, Fong L, et al. Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). Ann Oncol. 2019;30:v366-v7.

31. Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312-22.

32. Powles T, O’Donnell PH, Massard C, Arkenau HT, Friedlander TW, Hoimes CJ. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study. JAMA Oncol. 2017;14;3(9):e172411.

33. Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1574-88.

34. AstraZeneca. Voluntary withdrawal of Imfinzi indication in advanced bladder cancer in the US 2021 [Available from: https://www.astrazeneca.com/content/ astraz/media-centre/press-releases/2021/voluntarywithdrawal- imfinzi-us-bladder-indication.html.

35. Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an openlabel, phase 1 trial. Lancet Oncol. 2018;19(1):51-64.

36. Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based firstline (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. J Clin Oncol. 2020;38(18_suppl):LBA1-LBA.

37. Galsky MD, Mortazavi A, Milowsky MI, George S, Gupta S, Fleming MT, et al. Randomized Double- Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. J Clin Oncol. 2020;38(16):1797-806.

38. A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations ClinicalTrials.gov [Available from: https://clinicaltrials. gov/ct2/show/NCT03390504.

39. Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma (PemCab) ClinicalTrials.gov [Available from: https://clinicaltrials.gov/ct2/show/NCT03534804.

40. Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer ClinicalTrials.gov [Available from: https://clinicaltrials. gov/ct2/show/NCT03272217.

41. Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2) ClinicalTrials.gov [Available from: https:// clinicaltrials.gov/ct2/show/NCT03473756.

42. Zhang T, Harrison MR, O’Donnell PH, Alva AS, Hahn NM, Appleman LJ, et al. A randomized phase 2 trial of pembrolizumab versus pembrolizumab and acalabrutinib in patients with platinum-resistant metastatic urothelial cancer. Cancer. 2020.

43. Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (CheckMate901) ClinicalTrials.gov [Available from: https://clinicaltrials.gov/ct2/show/NCT03036098.

44. Sharma P, Siefker-Radtke A, Braud F, Basso U, Calvo E, Bono P. Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. J Clin Oncol. 2019;17;37(19):1608-16.

45. Improve Checkpoint-blockade Response in Advanced Urothelial Cancer (ICRA) ClinicalTrials.gov [Available from: https://clinicaltrials.gov/ct2/show/NCT03871036.

46. Rosenberg JE, Flaig TW, Friedlander TW, Milowsky MI, Srinivas S, Petrylak DP, et al. Study EV-103: Preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. Journal of Clinical Oncology. 2020;38(6\_suppl):441.

47. A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU) (BAYOU) ClinicalTrials.gov [Available from: https://clinicaltrials.gov/ct2/show/ NCT03459846.

48. A Single-Arm Study of Bempegaldesleukin (NKTR 214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer (PIVOT-10) ClinicalTrials.gov [Available from: https:// clinicaltrials.gov/ct2/show/NCT03785925.

49. Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) ClinicalTrials.gov [Available from: https://clinicaltrials.gov/ct2/show/NCT03361865.

50. Long GV, Dummer R, Hamid O, Gajewski TF, Caglevic C, Dalle S. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 2019;1;20(8):1083-97.

51. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology bladder cancer 2020 [Version 5.2020:[Available from: https://www. nccn.org/professionals/physician_gls/pdf/bladder_ blocks.pdf.

52. Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859-66.

53. Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol. 2006;49(5):790-7.

54. Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432-8.

55. Westergren DO, Gårdmark T, Lindhagen L, Chau A, Malmström PU. A Nationwide, Population Based Analysis of Patients with Organ Confined, Muscle Invasive Bladder Cancer Not Receiving Curative Intent Therapy in Sweden from 1997 to 2014. J Urol. 2019;202(5):905-12.

56. Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur Urol. 2009;55(1):164-74.

57. Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer. 2006;107(3):506-13.

58. Gupta S, Agarwal N, Konety BR, Weight CJ, Thyagarajan B, Murugan PJ, et al. Phase II trial of neoadjuvant nivolumab with cisplatin and gemcitabine in muscle-invasive bladder cancer patients undergoing radical cystectomy. J Clin Oncol. 2018;36(6_ suppl):TPS528-TPS.

59. Hoimes CJ, Abouassaly R, Saltzman JN, Fleming MT, Hoffman-Censits JH, Byrd T, et al. HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC). J Clin Oncol. 2016;34(15_suppl):TPS4578-TPS.

60. Chanza NM, Roumeguere TA, Sideris S, Gil T, Peltier A, Awada A. Avelumab as neoadjuvant therapy in subjects with muscle-invasive urothelial carcinoma (AURA trial). J Clin Oncol. 2018;36(6_suppl):TPS535-TPS.

61. Gupta S, Sonpavde G, Weight CJ, McGregor BA, Gupta S, Maughan BL, et al. Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy. J Clin Oncol. 2020;38(6_ suppl):439.

62. Hoimes CJ, Adra N, Fleming MT, Kaimakliotis HZ, Picus J, Smith ZL, et al. Phase Ib/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): Final results from the cisplatin (C)- eligible cohort of HCRN GU14-188. J Clin Oncol. 2020;38(15_suppl):5047.

63. Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb SJ, Van Der Heijden MS, et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019;25(11):1706-14.

64. Kaimakliotis HZ, Adra N, Kelly WK, Trabulsi EJ, Lauer RC, Picus J, et al. Phase II neoadjuvant (N-) gemcitabine (G) and pembrolizumab (P) for locally advanced urothelial cancer (laUC): Interim results from the cisplatin (C)- ineligible cohort of GU14-188. J Clin Oncol. 2020;38(15_ suppl):5019.

65. Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucianò R, et al. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle- Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018;36(34):3353-60.

66. Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, et al. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. Eur Urol. 2020;77(4):439-46.

67. Briganti A, Gandaglia G, Scuderi S, Gallina A, Colombo R, Fossati N, et al. Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. Eur Urol. 2020;77(5):576-80.

68. Necchi A, Raggi D, Gallina A, Ross JS, Farè E, Giannatempo P, et al. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. Eur Urol. 2020;77(6):701- 10.

69. Grande E, Guerrero F, Puente J, Galante I, Duran I, Fuentes J, et al. DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores. J Clin Oncol. 2019;37(15_ suppl):TPS4588-TPS.

70. Grande E, Guerrero F, Puente J, Galante I, Duran I, Dominguez M, et al. DUTRENEO Trial: A randomized phase II trial of DUrvalumab and TREmelimumab versus chemotherapy as a NEOadjuvant approach to muscleinvasive urothelial bladder cancer (MIBC) patients (pts) prospectively selected by an interferon (INF)- gamma immune signature. J Clin Oncol. 2020;38(15_ suppl):5012.

71. Thibault C, Elaidi R, Vano YA, Rouabah M, Braychenko E, Helali I, et al. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO. Bull Cancer. 2020;107(5s):eS8-eS15.

72. Necchi A, Briganti A, Bianchi M, Raggi D, Giannatempo P, Luciano’ R, et al. PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscleinvasive urothelial bladder cancer (MIUBC). J Clin Oncol. 2018;36(15_suppl):TPS4595-TPS.

73. Collaboration ABCAM-a. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol. 2005;48(2):189-99; discussion 99-201.

74. Leow JJ, Martin-Doyle W, Rajagopal PS, Patel CG, Anderson EM, Rothman AT, et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur Urol. 2014;66(1):42-54.

75. Apolo AB, Rosenberg JE, Kim WY, Chen RC, Sonpavde G, Srinivas S, et al. Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation. J Clin Oncol. 2019;37(7_suppl):TPS504-TPS.

76. Galsky MD, Necchi A, Shore ND, Witjes F, Nam K, Sbar E, et al. Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905. J Clin Oncol. 2020;38(6_suppl):TPS593-TPS.

77. Siefker-Radtke AO, Steinberg GD, Bedke J, Nishiyama H, Fang X, Kataria R, et al. Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscleinvasive bladder cancer (MIBC): KEYNOTE-866. J Clin Oncol. 2020;38(6_suppl):TPS599-TPS.

78. Powles T, Meeks JJ, Galsky MD, Heijden MSVD, Nishiyama H, Al-Ahmadie H, et al. A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA). J Clin Oncol. 2019;37(15_ suppl):TPS4592-TPS.

79. Sonpavde G, Necchi A, Gupta S, Steinberg GD, Gschwend JE, Van Der Heijden MS, et al. ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with/without linrodostat mesylate for muscleinvasive bladder cancer. Future Oncol. 2020;16(2):4359- 68.

80. Cuellar MA, Medina A, Girones R, Valderrama BP, Font A, Juan-fita M, et al. Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy as bladder-sparing therapy in patients with localized muscle invasive bladder cancer: A SOGUG study. J Clin Oncol. 2020;38(15_suppl):TPS5097-TPS.

81. Balar AV, James ND, Shariat SF, Shore ND, Heijden MSVD, Weickhardt AJ, et al. Phase III study of pembrolizumab (pembro) plus chemoradiotherapy (CRT) versus CRT alone for patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-992. J Clin Oncol. 2020;38(15_suppl):TPS5093-TPS.

82. Weickhardt AJ, Foroudi F, Lawrentschuk N, Galleta L, Seegum A, Herschtal A, et al. Pembrolizumab with chemoradiotherapy as treatment for muscle invasive bladder cancer: A planned interim analysis of safety and efficacy of the PCR-MIB phase II clinical trial (ANZUP 1502). J Clin Oncol. 2020;38(6_suppl):485.

83. Gupta S, Maughan BL, Dechet CB, Lowrance WT, Neil BO, Kokeny KE, et al. NEXT: A phase II, open-label study of nivolumab adjuvant to chemoradiation in patients (pts) with localized muscle invasive bladder cancer. J Clin Oncol. 2020;38(6_suppl):TPS605-TPS.

84. Singh P, Tangen C, Efstathiou JA, Lerner SP, Jhavar SG, Hahn NM, et al. INTACT: Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806. J Clin Oncol. 2020;38(6_ suppl):TPS586-TPS.

85. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol. 2000;163(4):1124-9.

86. Han RF, Pan JG. Can intravesical bacillus Calmette- Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials. Urology. 2006;67(6):1216-23.

87. Shelley MD, Kynaston H, Court J, Wilt TJ, Coles B, Burgon K, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209-16.

88. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430-42.

89. Balar AV, Kulkarni GS, Uchio EM, Boormans J, Mourey L, Krieger LEM, et al. Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with highrisk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG). J Clin Oncol. 2019;37(7_suppl):350.

90. Wit RD, Kulkarni GS, Uchio EM, Krieger LEM, Boormans JL, Roumiguié M, et al. Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non– muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057. J Clin Oncol. 2019;37(15_suppl):4530.

91. U.S. Food & Drug Administration. FDA approves pembrolizumab for BCG-unresponsive, high-risk nonmuscle invasive bladder cancer 2020 [Available from: https://www.fda.gov/drugs/resources-informationapproved- drugs/fda-approves-pembrolizumab-bcgunresponsive- high-risk-non-muscle-invasive-bladdercancer.

92. Black PC, Catherine T, Lerner SP, McConkey DJ, Lucia MS, Woods M, et al. S1605: Phase II trial of atezolizumab in BCG-unresponsive nonmuscle invasive bladder cancer. J Clin Oncol. 2018;36(6_suppl):TPS527-TPS.

93. Black PC, Tangen C, Singh P, McConkey DJ, Lucia S, Lowrance WT, et al. Phase II trial of atezolizumab in BCGunresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816). J Clin Oncol. 2020;38(15_ suppl):5022.

94. Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, et al. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol. 2020;16(10):507-16.

95. Kamat AM, Shore ND, Hahn NM, Alanee S, Nishiyama H, Shariat S, et al. Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction. J Clin Oncol. 2019;37(7_suppl):TPS502- TPS.

96. Hahn NM, Chang SS, Meng M, Shore ND, Konety BR, Steinberg GD, et al. A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT. J Clin Oncol. 2019;37(7_suppl):TPS493-TPS.

97. Hahn NM, Chang S, Meng M, Shore ND, Konety BR, Steinberg GD, et al. A phase II, randomized study of nivolumab (NIVO), NIVO plus linrodostat mesylate, or NIVO plus intravesical bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, nonmuscle invasive bladder cancer (NMIBC): CheckMate 9UT. J Clin Oncol. 2020;38(15_suppl):TPS5090-TPS.

98. Davies BJ, Hwang TJ, Kesselheim AS. Ensuring Access to Injectable Generic Drugs - The Case of Intravesical BCG for Bladder Cancer. N Engl J Med. 2017;376(15):1401-3.

99. Messing EM. The BCG Shortage. Bladder Cancer. 2017;3(3):227-8.

100. Bandari J, Maganty A, MacLeod LC, Davies BJ. Manufacturing and the Market: Rationalizing the Shortage of Bacillus Calmette-Guérin. Eur Urol Focus. 2018;4(4):481-4.

101. Valgus J, Singer EA, Berry SR, Rathmell WK. Ethical challenges: managing oncology drug shortages. J Oncol Pract. 2013;9(2):e21-3.

102. Roupret M, Neuzillet Y, Bertaut A, Pignot G, Houede N, Champiat S, et al. ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37). J Clin Oncol. 2019;37(15_suppl):TPS4589-TPS.

103. Santis MD, Abdrashitov R, Hegele A, Kolb M, Parker S, Redorta JP, et al. A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guérin (BCG) versus BCG alone in highrisk, BCG-naïve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC). J Clin Oncol. 2019;37(7_ suppl):TPS500-TPS.

104. Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet. 2020;395(10232):1268-77.

105. Jamil ML, Deebajah M, Sood A, Alanee S. Combination of pembrolizumab and BCG treatment after endoscopic ablation of high-risk superficial upper urinary tract urothelial carcinoma in patients not candidates for radical nephroureterectomy: protocol for phase-II study. BMJ Open. 2019;9(12):e027066.

106. Hussain MHA, Powles T, Albers P, Castellano D, Daneshmand S, Gschwend J, et al. IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in highrisk muscle-invasive urothelial carcinoma (MIUC). J Clin Oncol. 2020;38(15_suppl):5000.

107. Balar AV, Castellano D, O’Donnell PH, Grivas P, Vuky J, Powles T. First-line pembrolizumab in cisplatinineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 2017;1;18(11):1483-92.

108. Administration USFD. FDA Alerts Health Care Professionals and Oncology Clinical Investigators about an Efficacy Issue Identified in Clinical Trials for Some Patients Taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as Monotherapy to Treat Urothelial Cancer with Low Expression of PD-L1 2018 [Available from: https://www.fda.gov/drugs/drug-safety-and-availability/ fda-alerts-health-care-professionals-and-oncologyclinical- investigators-about-efficacy-issue.

109. Administration USFD. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) 2020 [Available from: https://www.fda.gov/ medical-devices/vitro-diagnostics/list-cleared-orapproved- companion-diagnostic-devices-vitro-andimaging- tools.

110. Rui X, Gu TT, Pan HF, Zhang HZ. Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis. Int Immunopharmacol. 2019;67:378-85.

111. Aggen DH, Drake CG. Biomarkers for immunotherapy in bladder cancer: a moving target. J Immunother Cancer. 2017;5(1):94.

112. Rizvi H, Sanchez-Vega F, La K, Chatila W, Jonsson P, Halpenny D, et al. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. J Clin Oncol. 2018;36(7):633-41.

113. Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, et al. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers. J Clin Oncol. 2018;36(17):1685-94.

114. Iyer G, Audenet F, Middha S, Carlo MI, Regazzi AM, Funt S, et al. Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. J Clin Oncol. 2017;35(15_suppl):4511.

115. Schneider B, Glass Ä, Jagdmann S, Hühns M, Claus J, Zettl H, et al. Loss of Mismatch-repair Protein Expression and Microsatellite Instability in Upper Tract Urothelial Carcinoma and Clinicopathologic Implications. Clin Genitourin Cancer. 2020.

116. Administration USFD. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication 2017 [Available from: https://www.fda. gov/drugs/resources-information-approved-drugs/ fda-grants-accelerated-approval-pembrolizumab-firsttissuesite- agnostic-indication.

117. Administration USFD. FDA approves pembrolizumab for first-line treatment of MSI-H/dMMR colorectal cancer 2020 [Available from: https://www.fda.gov/drugs/drugapprovals- and-databases/fda-approves-pembrolizumabfirst- line-treatment-msi-hdmmr-colorectal-cancer.

118. Khan OF, Monzon J. Diagnosis, monitoring, and management of adverse events from immune checkpoint inhibitor therapy. Curr Oncol. 2020;27(Suppl 2):S43-s50.

119. Mangan BL, McAlister RK, Balko JM, Johnson DB, Moslehi JJ, Gibson A, et al. Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. Br J Clin Pharmacol. 2020;86(9):1778- 89.

120. Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol.2018;36(17):1714-68.

121. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23-34.

122. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015;33(18):2092-9.

Author Information X